CFRXQ — CONTRAFECT Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
U.S. STOCKS ON THE MOVE-Senti Biosciences, Autoliv, Nexstar Media
U.S. STOCKS ON THE MOVE-Iovance, American Express, HCA Healthcare
U.S. STOCKS ON THE MOVE-Visa, BuzzFeed, Hasbro
ContraFect denied request to keep Nasdaq listing, shares down
Brief: Contrafect Corp Nasdaq Staff Informed Co That Staff Had Determined To Deny Co's Request For Continued Listing On Nasdaq Capital Market
Brief: Contrafect Provides Update From The Futility Analysis Of The Phase 3 Disrupt Study Of Exebacase
Brief: ContraFect Announces Pricing Of $7.0 Million Registered Direct Offering And Concurrent Private Placement
Brief: ContraFect Corp Says On Nov 22, Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
ContraFect Corp reports results for the quarter ended in September - Earnings Summary
ContraFect Corp expected to post a loss of 23 cents a share - Earnings Preview
Brief: ContraFect Announces Multiple Publications Highlighting The Potential Utility Of Lysins For The Treatment Of Bone And Joint Infections
Brief: ContraFect Announces Presentation Of New Clinical Data From A Study On Patients With Chronic Knee Prosthetic Joint Infection
Brief: Contrafect Corp - On August 25, Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Contrafect reports Q2 results
Brief: Contrafect announces publication on Exebacase and CF-296 demonstrating potent in vivo antimicrobial activity in implant-associated MRSA osteomyelitis
ContraFect Corp expected to post a loss of 37 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-First Republic Bank, Canoo Inc, CytomX Therapeutics Inc
ContraFect set to hit record low after being asked to stop lead drug trial
U.S. RESEARCH ROUNDUP- Boeing, Magnite, Unity Software